The clinical responses observed following treatment with immune checkpoint inhibitors
(ICIs) support immunotherapy as a potential anticancer treatment. However, a large …

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature
myeloid cells with an immune suppressive phenotype. They represent a critical component …

Immune checkpoint inhibitors (ICIs) are starting to transform the treatment for patients with
advanced cancer. The extensive application of these antibodies for various cancer obtains …

Immune checkpoint inhibitors (ICI) used for cancer immunotherapy were shown to boost the
existing anti-tumor immune response by preventing the inhibition of T cells by tumor cells …

The emergence of immunotherapy has been an astounding breakthrough in cancer
treatments. In particular, immune checkpoint inhibitors, targeting PD-1 and CTLA-4, have …

Myeloid-derived suppressor cells (MDSCs) are a group of heterogeneous cells which are
abnormally accumulated during the differentiation of myeloid cells. Immunosuppression is …

Suppression of antitumor immune responses is one of the main mechanisms by which tumor
cells escape from destruction by the immune system. Myeloid-derived suppressor cells …

Immune-checkpoint blockade (ICB) demonstrated inspiring effect and great promise in anti-
cancer therapy. However, many obstacles, such as drug resistance and difficulty in patient …

The goal of achieving measurable response with cancer immunotherapy requires
counteracting the immunosuppressive characteristics of tumors. One of the mechanisms that …

The primary function of myeloid cells is to protect the host from infections. However, during
cancer progression or states of chronic inflammation, these cells develop into myeloid …